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and hepatic toxicity, but randomized trials are needed to assess its efficacy.
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ince March 11, 2020, Spain and many other
countries have seen a 3-wave pattern in reported
cases of SARS-CoV2 COVID-19.1,2 As of February 17,
2021, more than 3,105,000 cases of COVID-19 and
55,000 deaths due to the infection have been reported
in Spain, being the seventh most affected country.1,3
Kidney transplant (KT) recipients appear to be at
notable high risk for critical COVID-19 illness due to
long-term immunosuppression, age, coexisting comor-
bidities, and frequent contact with health care facil-
ities.4–8 Among 35,183 prevalent KT recipients in
Spain,9 almost 1700 cases of COVID-19 have been re-
ported by the Spanish Society of Nephrology (S.E.N.)
registry. This results in a global incidence of 4.8%,10
similar to 6.1% reported in the general population.1
Treatment for COVID-19 has been a matter of debate
during the pandemic spread, including both antiviral
and anti-inflammatory drugs.11–17 Remdesivir is a
prodrug of an adenosine analog that has demonstrated
antiviral activity against a broad range of RNA virus
families, including coronaviruses. This drug has shown
nanomolar in vitro activity against SARS-CoV2 in hu-
man airway epithelial cells and clinical and virologic
efficacy in a primate model.18 Some clinical trials
showed that remdesivir was superior to placebo in
shortening the time to recovery in adults hospitalized
with COVID-19.16,17
However, all remdesivir trials have excluded pa-
tients with severe acute kidney injury (AKI), chronic
kidney disease (CKD) with an estimated glomerular
filtrate rate (eGFR) <30 ml/min per 1.73 m2, or those on
renal replacement therapy (RRT). There are concerns
about the potential toxicity of remdesivir in patients
with renal impairment related both to dose-dependent
direct tubular damage produced by remdesivir in
experimental studies and the potential accumulation of
its sulfobutylether-b-cyclodextrin (SBECD) carrier.19
The most common adverse events described in pa-
tients treated with remdesivir are increased hepatic
enzymes, diarrhea, rash, renal impairment, and hypo-
tension.20,21 Particularly, the development of AKI has
been described in up to 22.8% of patients treated with
remdesivir.21,22 Nevertheless, randomized clinical trials
presented a comparable incidence of AKI between
remdesivir and placebo.16,23 Moreover, recent studies
reported remdesivir was well tolerated in patients withAKI and CKD, including those on RRT.24,25 Assessment
of drug-induced nephrotoxicity is particularly chal-
lenging because COVID-19 also bears frequent renal
complications.26–28
Remdesivir has scarcely been used in KT patients
with COVID-19.5,7,24,29 KT recipients have only 1
functioning kidney most of the time, with reduced
eGFR compared with the general population, and
frequently receive calcineurin inhibitors, which
compromise the glomerular blood flow. Minimal data
are currently available on the use and safety of
remdesivir in this at-risk population.24 Here, we pre-
sent the results of a Spanish multicenter study gath-
ering data of 51 KT recipients treated with remdesivir
for COVID-19. Their outcomes, safety profile, renal
impairment, and tacrolimus interaction were assessed.
METHODS
Patients
A Spanish registry comprising dialysis and KT patients
with a confirmed diagnosis of COVID-19 started on
March 18, 2020 (S.E.N. COVID-19 registry), as previ-
ously described.10 Only patients diagnosed with posi-
tive reverse-transcriptase polymerase chain reaction
assay of a specimen collected on a nasopharyngeal swab
or bronchoalveolar lavage were included. Of these, KT
patients who received remdesivir treatment were
included in this study. Until February 1, 2021, 48 were
identified to have received remdesivir in 26 different
hospitals. Each center was contacted and invited to
participate in the study by completing an expanded
retrospective database with more detailed data from
this cohort. Twenty-four centers completed the data-
base for 43 patients, and 8 additional patients were
included, resulting in a final number of 51 patients.
The median time of follow-up since the onset of
symptoms to recovery/death was 25 days (interquartile
range [IQR], 16–35 days) and to the end of follow-up
was 49 days (IQR, 34–68 days).
Data Collection and Definitions
The characteristics and variables included in the
COVID-19 registry have been previously reported.8,30
Added in the expanded database were more specific
and detailed data regarding demographics (recipient
age, sex, race, and comorbidity), time after KT, timeKidney International Reports (2021) 6, 2305–2315
Table 1. Baseline characteristics among kidney transplant
recipients with COVID-19 infection who received remdesivir
Variablesa All (N [ 51)
Baseline characteristics
Recipient age, y 60  13
Recipient age $65 y 20 (39.2)
Male sex 33 (65.7)
White race 36 (70.6)
Underlying diabetic kidney disease 8 (15.7)
First kidney transplant 43 (84.3)
History of smoking 5 (9.8)
Comorbidities
Lung disease 6 (11.8)
Ischemic heart disease 7 (13.7)
Arterial hypertension 42 (82.4)
Diabetes mellitus 16 (31.4)
History of cancer 7 (13.7)
Obesity (body mass index >30 kg/m2) 12 (23.5)
ACEi or ARB treatment 17 (33.3)
Immunosuppressive therapy
Thymoglobulin induction 15 (29.4)




mTOR inhibitor 7 (13.7)
Baseline kidney function (before admission)
Serum creatinine, mg/dl 1.4  0.4
eGFR CKD-EPI, ml/min per 1.73 m2 53.8  18.7
eGFR <30 ml/min per 1.73 m2 2 (3.9)
At admission
Time from KT to COVID-19 diagnosis, y 4.5 (1–10.5)
Time from KT #6 months 9 (17.6)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR
CKD-EPI, estimated glomerular filtrate rate calculated using Chronic Kidney Disease
Epidemiology Collaboration equation; KT, kidney transplantation, mTOR, mammalian
target of rapamycin.
aData correspond to clinical characteristics before hospital admission.
Continuous data are presented as mean  SD or median (interquartile range) and
categorical data as n (%).
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waves, respiratory situation, including arterial partial
pressure of arterial oxygen/fraction of inspired oxygen
ratio (PaO2/FIO2) index, acute respiratory distress syn-
drome, oxygen saturation by pulse oximetry, or
pneumonia demonstrated by X-ray imaging; remdesivir
treatment (days of remdesivir treatment, remdesivir
dose), inflammatory markers, maintenance immuno-
suppressive treatment at admission, tacrolimus blood
levels, kidney function, liver parameters, and adverse
events. These variables were chosen based on their
clinical relevance and previous results obtained from
our group.
Criteria for remdesivir treatment were based on the
protocol of each hospital, although all patients pre-
sented with one of the following: requirement of sup-
plemental oxygen, rapidly progressive acute
respiratory distress syndrome (defined as PaO2/FIO2
index <300) and/or bilateral pneumonia with rapidly
increased levels of inflammatory markers, such as C-
reactive protein (CRP), interleukin-6, D-dimer, ferritin,
or lactic acid dehydrogenase. Most patients had given
oral informed consent before remdesivir administra-
tion. Remdesivir dose regimens were based on the
protocol of each hospital. The most common dosing
regimen was 200 mg on day 1, followed by 100 mg on
days 2 through 5.
Obesity was defined as body mass index >30 kg/m2.
The immunosuppression regimen corresponds to that
received at the time of COVID-19 diagnosis. AKI was
defined following Kidney Disease: Improving Global
Outcomes criteria for stage 1, stage 2, and stage 3.31 The
last serum creatinine (SCr) value before admission was
considered as the baseline to assess the incidence of
AKI. Drug-induced liver injury was defined according
to a grading system developed by the Drug-Induced
Liver Injury Network. Grade 1 or mild was defined
as raised serum alanine aminotransferase (ALT) or
alkaline phosphatase levels, or both, but total serum
bilirubin <2.5 mg/dl and no coagulopathy (interna-
tional normalized ratio <1.5). No patients presented
severity grades 2 to 5.32 Respiratory symptoms
included cough, sneezing, and rhinorrhea but excluded
dyspnea, which was collected separately. Respiratory
status was recorded through PaO2/FIO2 when available
(n ¼ 21). If data to calculate the PaO2/FIO2 index were
missing, oxygen saturation by pulse oximetry was
considered (n ¼ 28).
Clinical follow-up and laboratory tests were
collected at 5 points: admission, when remdesivir was
administered, early after remdesivir infusion (median, 2
days; IQR, 1–4 days), at discharge, and at early follow-
up after discharge (median, 28 days; IQR, 17–57 days).
Additionally, we collected the last SCr and tacrolimusKidney International Reports (2021) 6, 2305–2315levels before admission to assess the incidence and
outcomes of AKI and tacrolimus levels variability.
Outcomes were assessed as COVID-19–related mor-
tality or recovery until February 10, 2021. Recovery
was defined as hospital discharge or clinical judgment
based on 1 negative reverse-transcriptase polymerase
chain reaction result and symptom resolution. Time to
events was defined as days from COVID-19 diagnosis to
death or recovery.
The study was approved by the local Ethical Com-
mittee at Hospital del Mar, Barcelona, Spain, and con-
ducted according to the guidelines as dictated by the
Declaration of Helsinki. All data were recorded
anonymously.
Statistical Analysis
Categorical data are summarized as counts and per-
centages. According to their distribution, continuous
data are expressed as mean and SD or median and IQR.2307







1st wave (March–June, 2020) 3 (5.9)
2nd wave (July–December, 2020) 46 (90.2)
3rd wave (since January, 2021) 2 (3.9)
Time between symptoms onset and admission, d 3 (2–5)
Clinical features at COVID-19 diagnosis
Fever 40 (78.4)
Dyspnea 36 (70.6)
Cough, expectoration, and/or rhinorrhea 40 (78.4)
Gastrointestinal symptoms 19 (37.3)
Respiratory situation
PaFi, mm Hg (n ¼ 21) 300 (249–360)
ARDS (PaFi <300) 10 (19.6)
Oxygen saturation, % (n ¼ 28) 93 (88.3–96.8)
PaFi <300 or oxygen saturation #94% (n ¼ 45) 26 (51)
Pneumonia demonstrated by X-ray imaging 46 (90.2)
Blood test at admission
Lymphocytes, 103/ml (n ¼ 51) 0.9  1.2
C-reactive protein, mg/L (n ¼ 50) 50.5 (7.6–109.5)
Procalcitonin, ng/ml (n ¼ 38) 0.3 (0.1–0.8)
Interlrukin-6, pg/ml (n ¼ 34) 42.8 (17.6–106.7)
Lactate dehydrogenase, IU/l (n ¼ 46) 295 (238.5–361.5)
Ferritin, ng/ml (n ¼ 45) 520 (295.5–1,134.5)
D-dimer, mg/l (n¼45) 667 (225–1,261)
Serum creatinine, mg/dl (n ¼ 51) 1.68  0.7
Bilirubin, mg/dl (n ¼ 45) 0.63 (0.4–0.88)
Alanine aminotransferase, IU/l (n ¼ 49) 22 (14–31.5)
Aspartate aminotransferase, IU/l (n ¼ 45) 28 (18–33.5)
ARDS, acute respiratory distress syndrome, PaFi, partial pressure of arterial oxygen/
fraction of inspired oxygen.
Categorical data are presented as n (%) and continuous date as mean  SD or median
(interquartile range).
CLINICAL RESEARCH A Buxeda et al.: Remdesivir in KT Recipients With COVID-19Univariate analyses were performed according to var-
iables normality, using c2 or Fisher exact tests to
analyze categorical variables, the Student t test for
continuous variables with normal distribution, and the
Mann-Whitney test U test for abnormal distribution
data. Patient survival analysis according to age was
performed using Kaplan-Meier survival curves,
applying the log-rank test. Statistical analysis was
performed using SPSS 22.0 software (IBM, Armonk,
NY). A P value of <.05 was considered statistically
significant. We used GraphPad Prism 7 (GraphPad
Software, San Diego, CA) for data presentation.RESULTS
Patient Characteristics
During the observation period (March 12, 2020–
February 1, 2021), 51 fully documented patients with
COVID-19 had been treated with remdesivir and were
included in the study. Baseline characteristics of the
study population are summarized in Table 1. The mean2308recipient age at the time of the COVID-19 diagnosis was
60  13 years. Most recipients were men (65.7%),
Caucasian (70.6%), and with a high prevalence of hy-
pertension (82.4%). Diabetes mellitus was present in
31.4% of the cohort, ischemic heart disease in 13.7%,
and 11.8% had previous pulmonary disease. Tacroli-
mus plus mycophenolate-based immunosuppression
was the most common therapy at admission (68.6% of
recipients). Median time from KT to COVID-19 infec-
tion was 4.5 years, and 17.6% had received their
transplant within the last 6 months. Before admission,
the mean SCr levels were 1.4  0.4 mg/dl and a mean
eGFR of 53.8  18.7 ml/min per 1.732.
Clinical Characteristics and Laboratory Findings
at COVID-19 Presentation
Table 2 summarizes clinical characteristics and labora-
tory data. The COVID-19 diagnosis in 90% of patients
occurred during the second wave. The median time
between the onset of symptoms and hospital admission
was 3 days (IQR, 2–5 days). There was just 1 nosoco-
mial SARS-CoV2 infection. The most common clinical
manifestations at admission were fever and respiratory
symptoms (78.4%), followed by dyspnea (70.6%) and
gastrointestinal symptoms (37.3%). Chest X-ray imag-
ing showed pneumonia in 90% of patients. Twenty-six
patients (51%) presented acute respiratory distress
syndrome or oxygen saturation #94% at admission.
Analytical parameters at admission showed lympho-
penia and elevated inflammatory markers.
Treatment of COVID-19
Changes in immunosuppression strategy are displayed
in Figure 1. Up to 86.3% of patients had at least 1 of
their immunosuppressants withdrawn at admission.
Mycophenolate or mammalian target of rapamycin in-
hibitor withdrawal was the most frequent immuno-
suppression reduction strategy (49%), and only 4
patients maintained triple immunosuppressant therapy
during admission. Calcineurin inhibitor was with-
drawn in 39.6% of patients treated with this therapy.
Regarding anti–COVID-19 therapies, remdesivir was
administered at a median time of 2 days after admis-
sion. Of the 15 patients who required intensive care
unit management, remdesivir was generally adminis-
tered before admission, because the median time since
hospital admission to intensive care unit was 4.5 days.
A trend toward a decrease in the mean duration of
hospitalization was seen in the 27 patients in whom the
drug was initiated within 48 hours of admission (12.5
days; IQR, 9–30 days) compared with 20 patients who
received remdesivir beyond the first 48 hours after
admission (22.5 days; IQR, 15–34; P ¼ .07). Similarly,
the duration of oxygen therapy in the first group wasKidney International Reports (2021) 6, 2305–2315
Figure 1. Changes in immunosuppressive treatment after admission with SARS-CoV2 infection. (a) Changes in the number of immunosup-
pressant drugs before hospital admission (left) and after admission (right). The number of immunosuppressant agents is color-coded. (b)
Immunosuppressive withdrawal management after admission. CNI, calcineurin inhibitor; MPA, mycophenolate acid; mTORi, mammalian target
of rapamycin inhibitor.
A Buxeda et al.: Remdesivir in KT Recipients With COVID-19 CLINICAL RESEARCHslightly shorter (10 days [IQR, 5–23 days] vs. 16 days
[IQR, 10–25 days], P ¼ .21). Nevertheless, we did not
observe a lower mortality rate in patients who initiated
the drug earlier (11.1% vs. 24%, P ¼ .21). The most
frequent remdesivir regimen was 200 mg on day 1 and
100 mg on days 2 through 5 (56%) (Figure 2).
Most patients received combined treatment with
steroid pulses, and up to 70.6% received antibiotics
(other than azithromycin) due to confirmed or sus-
pected bacterial coinfections. Tocilizumab was admin-
istered in 14 patients, and most of them received the
drug after remdesivir treatment, with a median time
from admission to the administration of tocilizumab of
5 days. Azithromycin, hydroxychloroquine, and rito-
navir/lopinavir were less frequently used (Table 3).General Outcomes and Safety End Points
Ninety percent of patients required supplemental ox-
ygen. The respiratory failure led to noninvasive me-
chanical ventilation support in 19 patients (8 of them
outside an intensive care unit facility), and 9 required
endotracheal intubation (Table 3). The fatality rate was
18.9%, although markedly higher in recipients
aged $65 years (45% vs. 3.2%, P < .001) (Figure 3).Kidney International Reports (2021) 6, 2305–2315AKI was present in 27.7% of the cohort. Most pa-
tients presented with AKI stage 1 (57.1%), and only 1
patient required RRT, with complete recovery of renal
function at discharge. Of 14 recipients with AKI, 8
presented the peak SCr before the initiation of remde-
sivir, and therefore, renal function abnormalities could
not be attributable to the drug. The mean SCr levels at
remdesivir administration were 1.4  0.5 mg/dl, with a
mean eGFR of 57.5  18.8 ml/min per 1.73 m2. Only
8.5% of patients had eGFR <30 ml/min per 1.73 m2
when remdesivir was initiated. AKI after remdesivir
initiation happened in 11.7%. Of note, T-cell mediated
rejection developed in 1 patient, and another patient
presented thrombotic microangiopathy.
No patients required discontinuation of remdesivir
therapy because of renal impairment. The dynamic
profile of SCr after remdesivir treatment is detailed in
Figure 4a. Tacrolimus trough levels were analyzed
before and after remdesivir use in 22 patients who
maintained the treatment during admission. We found
a significant decrease in tacrolimus levels after remde-
sivir treatment (6.9 ng/ml [IQR, 5.7–8.8 ng/ml] vs. 5.2
ng/ml [IQR, 4.2–8.2 ng/ml], P ¼ .04), although the
tacrolimus dose was reduced in 11 of 22 patients at
admission.2309
Figure 2. Remdesivir regimens. Remdesivir dose regimens based on the protocol of each hospital. The most frequent remdesivir regimen was
200 mg (MG) on day 1 and 100 mg on days 2 through 5.
CLINICAL RESEARCH A Buxeda et al.: Remdesivir in KT Recipients With COVID-19Evolution of liver function is depicted in Figure 4b–d.
Baseline liver function abnormalities (elevated aspartateTable 3. Management and outcomes of kidney transplant recipients





Time since symptoms onset to remdesivir treatment, d 7 (5–9)
Time since admission to remdesivir treatment, d 2 (1–4)
Azithromycin 6 (11.8)
Other antibiotics 36 (70.6)
Steroids (methylprednisolone bolus or dexamethasone) 49 (96.1)





Time since admission to tocilizumab treatment, d 5 (4–7)
Kidney function at remdesivir initiation
Serum creatinine, mg/dl 1.4  0.5
eGFR CKD-EPI, ml/min per 1.73 m2 57.5  18.8
eGFR <30 ml/min per 1.73 m2 4 (8.5)
Outcomes and follow-up
Supplemental oxygen 46 (90.2)
ICU admission 15 (29.4)
Time since hospital admission to ICU admission, d 4.5 (2.8–14.3)
Noninvasive mechanical ventilation 19 (37.3)
Endotracheal intubation 9 (17.6)
AKIa 14 (27.5)
AKI stage 1 8 (57.1)
AKI stage 2 4 (28.6)
AKI stage 3 2 (14.3)
AKI with renal replacement therapy need 1 (2)
Time since hospital admission to SCr peak in patients with AKI, d 5 (0–8.5)
Time since remdesivir to SCr peak in patients with AKI, d 1 (4.5 to 8)
Acute rejection 1 (2)
X-ray improvement after remdesivir (n ¼ 32) 13 (25.5)
AKI, acute kidney injury, eGFR CKD-EPI, estimated glomerular filtrate rate calculated
using Chronic Kidney Disease Epidemiology Collaboration equation; ICU, intensive care
unit; SCr, serum creatinine.
aAKI stages 1, 2 and 3 outline the most severe AKI stage during hospital admission.
Continuous data are presented as mean  SD or median (interquartile range) and
categorical data as n (%).
2310aminotransferase [AST] and ALT levels) were observed
in 4 patients before starting remdesivir. Only 2 patients
were found to have newly occurring grade 1 elevation of
AST/ALT, and liver function remained stable in 95.7%
of patients after the drug administration. In the 4 pa-
tients with raised baseline AST and ALT levels,
remdesivir therapy was not associated with worsening
transaminitis.
We observed a significant decrease in CRP levels
after treatment (53.6 mg/l [IQR, 9.1–114.7 mg/l] vs. 7.2
mg/l [IQR, 1.4–31.5 mg/l]), whereas other inflammatory
markers remained stable (Supplementary Table S1).
Finally, no rash or hypotension episodes were
described after remdesivir administration in our
cohort.
DISCUSSION
Our study reports the largest cohort of KT recipients
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Figure 3. Patient survival according to age in kidney transplant
recipient with COVID-19 treated with remdesivir. Kaplan-Meier curve
shows mortality rates of kidney transplantation patients with COVID-
19 according to recipient age (<65 years vs.$65 years). The median
time between the onset of symptoms and the end of follow-up was
49 days (interquartile range, 34–68 days).




































































































*  P = .06 (vs ALT at admission)









































#P < .00 (vs. Basal Cr)
$P < .00 (vs. Basal Cr)
Serum creaninea
Figure 4. Dynamic profile of kidney and liver function regarding COVID-19 infection evolution and remdesivir use. (a) Serum creatinine (Cr)
levels at different time points: basal (preadmission), hospital admission (Adm), remdesivir administration (RDV), 72 hours after remdesivir, and
early follow-up after discharge. Laboratory findings regarding liver function for (b) bilirubin, (c) aspartate aminotransferase (AST), and (d)
alanine aminotransferase (ALT) between different time points: admission, remdesivir administration, 72 hours after remdesivir, and early follow-
up after discharge. NS, not significant.
A Buxeda et al.: Remdesivir in KT Recipients With COVID-19 CLINICAL RESEARCH51 patients were analyzed, with an overall mortality of
18.9%, being markedly higher in recipients aged $65
years. Most patients were diagnosed during the second
wave. AKI developed in 27% of patients during the
study period, but only 11.7% was potentially attrib-
uted to the drug. Remdesivir therapy was not with-
drawn because of renal impairment. We observed no
clinically significant ALT/AST increase after patients
received the drug.
The evolution of the pandemic in Spain has occurred
a 3-wave pattern in reported cases of COVID-19, with
some differences in clinical features.1,2 Anti–COVID-19
therapies and epidemiologic characteristics of KT with
SARS-CoV2 infection have changed between waves due
to a better knowledge of the disease.10 Anti–COVID-19
therapies, such as hydroxychloroquine or ritonavir/
lopinavir, are no longer used, whereas pulse steroid
therapy has increased in consonance with the current
scientific data10–14 as well as remdesivir.Kidney International Reports (2021) 6, 2305–2315Developed initially as a possible treatment for the
Ebola virus disease, remdesivir has shown promising
results against SARS-CoV2 in reducing hospital stay
and mortality.15–17 However, a later study reported no
effect on hospitalized patients with COVID-19, as
indicated by overall mortality, initiation of ventilation,
and duration of hospital stay.33 The United States Food
and Drug Administration and the European Medicines
Agency granted remdesivir emergency use during the
first wave,34,35 but our study shows that remdesivir
treatment in KT has been predominantly administered
during the second wave.
The most common adverse events described in pa-
tients treated with remdesivir are increased hepatic
enzymes, diarrhea, rash, AKI, and hypotension.20,21
Serious adverse events were reported in 24.6% of 532
remdesivir-treated patients versus 31.6% of 516 pla-
cebo recipients in a randomized trial.16 The drug was
withdrawn early because of adverse events in 9.8% of2311
CLINICAL RESEARCH A Buxeda et al.: Remdesivir in KT Recipients With COVID-19patients. No KT patient in our experience required
remdesivir interruption due to adverse events.
The presumed toxicity in patients with renal
impairment is attributed to both remdesivir direct
tubular damage in experimental studies and SBECD
carrier accumulation. SBECD is a solubility-enhancing
agent predominantly excreted through glomerular
filtration. Studies in animals have associated SBECD
accumulation with renal tubule obstruction due to
vacuolation at doses 50-fold higher than those typically
administered in humans. However, the short duration
of treatment (5–10 days) and relatively low concen-
tration of SBECD carrier used in COVID-19 treatment
(100 mg of lyophilized powder of remdesivir contains 3
g of SBECD, and 100 mg solution of remdesivir contains
6 g of the carrier) would be far below SBECD recom-
mended safety thresholds of 250 mg/kg per day.19 Of
note, most patients in our cohort received lyophilized
remdesivir powder.
Probably due to this potential nephrotoxicity, pa-
tients with CKD, including KT recipients, are under-
represented in the randomized studies with remdesivir.
For this reason, we aimed to evaluate the potential
toxicity related to this drug in these patients. Renal
impairment developed in 27% of our KT cohort, in line
with previous reported evidence.5,7,30 However, nearly
half of the patients in our cohort cases presented the
peak SCr before remdesivir was initiated, including a
case of acute rejection, and therefore, renal function
abnormalities could not be attributable to the drug.
Of interest, all patients with AKI who survived
recovered baseline graft function at the end of follow-
up. Antinori et al.21 described up to 22.8% of AKI in a
cohort of patients treated with remdesivir. Nonethe-
less, as the authors postulated, the assessment of drug-
induced nephrotoxicity is particularly challenging
because COVID-19 also displays frequent renal com-
plications, and randomized clinical trials have pre-
sented a comparable incidence of AKI between
remdesivir and placebo.16,23,26–28
When we evaluated the potential hepatic toxicity,
only 2 patients were found to have newly occurring
grade 1 elevations of AST/ALT. Moreover, remdesivir
therapy was not associated with worsening trans-
aminitis in those patients with raised baseline AST and
ALT levels. Similar results have been previously
described in patients with AKI, CKD, or RRT.24,25
The use and safety of remdesivir as part of COVID-
19 management was previously reported in 16 pa-
tients from 2 KT cohorts.24,29 Elec et al.29 analyzed 8
patients, with 6 of them presenting slightly decreased
eGFR upon discharge, which normalized within 1
month. Thakare et al.24 also included 8 KT patients
with COVID-19 treated with remdesivir. No renal2312function abnormalities attributable to the drug were
observed.24
More evidence is available from the use of remde-
sivir in non-KT patients with AKI, CKD, or RRT, sug-
gesting generally good tolerance.19,24,25,36,37 Aiswarya
et al.25 analyzed 48 hemodialysis patients and showed
no association with severe adverse events after 2 to 6
doses of remdesivir were administered. They did not
administer a loading dose of the drug because no evi-
dence of safety in patients with end-stage renal disease
was available.25
Other adverse effects reported after remdesivir use,
such as hypotension or rash,16,17 were not observed in
our cohort.
As for immunosuppression, we found it of utmost
importance to assess tacrolimus blood trough levels
variability in those patients treated with remdesivir
who maintained the drug during admission. As an in-
hibitor of cytochrome P450 3A4 in vitro, remdesivir
could potentially interact with tacrolimus. However, its
capacity to be a perpetrator to clinically significant
drug-drug interactions is limited by its rapid clearance
if kidney function is stable.38 Coadministration of
remdesivir with this nephrotoxic agent may increase
the plasma concentration of remdesivir metabolite,
SBECD carrier, or tacrolimus levels. In our cohort,
tacrolimus blood trough levels were significantly lower
after remdesivir treatment (6.9 vs. 5.2 ng/ml), but most
patients underwent dose reduction at admission. More
importantly, we found no tacrolimus accumulation in
the plasma due to remdesivir.
Those patients who initiated remdesivir more than
48 hours from admission showed a delayed discharge
(12.5 vs. 22.5 days since admission), which suggests
that early treatment onset could be associated with a
better clinical response. Aiswarya et al.25 found early
initiation of remdesivir (within 48 hours of hospital
admission) was associated with a decrease of 5.5 days in
the mean duration of hospitalization.25 These results
are consonant with what has been reported in the
general population.15,16,39
The mortality rate due to SARS-CoV2 infection in
Spain has progressively decreased throughout the
different waves. As of February 2020, the fatality rate
was 1.77% in the general population and 17% in the
KT population.1,3,10 Impaired kidney function, immu-
nosuppression, advanced age, pneumonia, and early
post-KT period have been identified as risk factors for
death.4,30,40–42 Our study cohort showed similar
COVID-19–related mortality to that previously
described in the overall cohort of KT by the S.E.N.
registry, including both hospital and nonhospitalized
infected patients. However, previously published
experience with remdesivir in COVID-19 patients withKidney International Reports (2021) 6, 2305–2315
A Buxeda et al.: Remdesivir in KT Recipients With COVID-19 CLINICAL RESEARCHAKI, CKD, or RRT displayed higher mortality rates of
20% to 44%.24,25,36 Univariate analysis comparing
survivors and nonsurvivors in our cohort identified
recipient age >65 years was associated with an
increased risk of death. In this group, the fatality rate
reached 45%. Multivariate analysis could not be per-
formed due to the inherent limitations of the sample
size.
Our study has several limitations. Owing to its
retrospective nature, some relevant clinical information
might be underreported, and residual confounders may
be present. The small sample size and the lack of a
comparison group preclude establishing definitive as-
sociations about safety or efficacy. Nonetheless, the
administration criteria were disease severity, and pa-
tients who received the drug presented a worse clinical
status than an eventual control group not receiving the
drug. Therefore, to avoid selection bias, we did not
include a contemporary or historical control group
because only a placebo-controlled trial can achieve this
aim and very few KT patients with COVID-19 were left
untreated when center protocols indicated remdesivir.
Some patients received other anti–COVID-19 treatments
(i.e., tocilizumab), and therefore, we cannot discard the
potential influence of these therapies in outcomes.
Finally, the patients included received variable dosing
of remdesivir.
Notwithstanding, to date, this is the largest series
focused on KT with COVID-19 treated with remdesivir,
and the extensive clinical and analytical workup con-
tributes to the understanding of the use and safety of
the drug in this at-risk population.
CONCLUSION
We present the largest cohort so far of KT recipients
treated with remdesivir for COVID-19 management.
Remdesivir was well tolerated, and there were no
significant safety concerns related to the drug
administration. More extensive, randomized
controlled trials evaluating the efficacy and safety of
remdesivir in KT patients with COVID-19 who
develop acute respiratory distress syndrome need to
be further assessed.
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